Expert InterviewNVS
Slingshot members are talking to an expert! The topic is:
Discussing investigational agents for C3 glomerulopathy (C3G) including pegcetacoplan and iptacopan
Executed on:Jan 15, 2025 3:30 PM EDT
Call Duration:30 minutes
Expert Profile
ExpertBlinded Expert
Institution: Mass General | Harvard
- Clinical researcher & clinician in academic nephrology practice; Nephrologist at Massachusetts General Hospital and Instructor in Medicine at Harvard Medical School.
- Currently manages 30+ patients each for IgAN and FSGS
- Conducts patient-oriented research in the areas of calciphylaxis, vascular calcification and hyponatremia, has authored over 50 peer-reviewed research articles, and research is funded by organizations including the American Kidney Fund & the National Kidney Foundation.
Interview Goal
This interview will explore the pivotal results of the Phase 3 VALIANT study for pegcetacoplan in treating C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN). Key areas of discussion will include the impact of pegcetacoplan on proteinuria, eGFR stabilization, C3c clearance, and its favorable safety profile. The conversation will also cover how these results could shape future treatment options for patients with these rare and severe kidney diseases.